ArticleNorthern clinics of Istanbul2022
Diagnostic and prognostic value of F-18 FDG PET/CT in patients with carcinoma of unknown primary.
Article in Northern clinics of Istanbul, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.
- Imaging of cancer of unknown primary: a systematic literature review of the past, present, and future.The British journal of radiology · 2025Pooled it
- Identifying the primary tumour in patients with cancer of unknown primary (CUP) using [European journal of nuclear medicine and molecular imaging · 2024Pooled it
- Incidental identification of elastofibroma dorsi in oncologic PET/CT imaging: a retrospective single-center analysis.Turkish journal of surgery · 2025Article
- Mucoepidermoid carcinoma of unknown primary in the head and neck: a case report and review of the literature.The Journal of laryngology and otology · 2025Review
- Article
- Complimentary Role of [18F]FDG and [18F]NaF-PET/CT in Evaluating Synchronous Thyroid Carcinoma and Parathyroid Adenoma with Brown Tumors.World journal of nuclear medicine · 2024Article
- Utility ofClinical Medicine Insights. Oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCarcinoma of unknown primary (CUP) is inability to detect primary tumor despite all imaging methods with a biopsy-proven tumor metastasis. In the present study, we aimed to investigate the diagnostic and prognostic value of F-18 fluorodeoxyglucose (F-18 FDG) positron emission tomography/computed tomography (PET/CT) in patients with CUP.
methodsThe patients with a diagnosis of CUP between November 2009 and January 2020 were evaluated retrospectively. A total of 155 patients (96 men and 59 women) were included in the study. Survival rates of the patients were evaluated by Kaplan-Meier and log-rank statistical analysis.
resultsThe correctly determined primary tumor by F-18 FDG PET/CT was found in 64 patients (41%) (true positive). F-18 FDG PET CT results were negative (false negative) in determining primary tumor localization in 14 (9%) patients whose had local disease. Of the 155 patients, 66 (42.5%) had true-negative results and 11 (7%) had false-positive results. The sensitivity of 82%, specificity of 86%, and accuracy of 84% were calculated. The SUV
conclusionF-18 FDG PET/CT is a useful method in the detection of primary tumor in patients with CUP. F-18 FDG PET/CT can be helpful the evaluation of the prognosis by showing the extent of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.